What happened with MED today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Medifast’s OPTAVIA programs help people manage weight and develop healthy habits by combining packaged nutrition products, such as OPTAVIA Fuelings, with meals clients prepare themselves and coach support. Clients pay Medifast for products shipped directly to them, and the company pays coaches commissions on product sales. Coaches attract and support clients rather than hold inventory or deliver orders. All revenue comes from sales in the United States.
The business depends on coaches bringing in clients and keeping them engaged. Its active earning coach network has been shrinking, while growing use of GLP-1 weight-loss medicines has reduced demand for its offerings. OPTAVIA also offers a GLP-1 Nutrition Support plan. Food and supplement rules govern its products, and direct-selling and advertising rules constrain the product and earnings claims the company and its coaches may make.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Herbalife competes with Medifast for weight-management customers; both sell nutrition products with personal guidance from independent networks. Watch Herbalife’s meal-replacement and weight-management sales for signs of demand for this supported approach to losing weight.
Medifast relies on LifeMD’s online clinical-care platform for its medically supported weight-management offering, including GLP-1 medications, while LifeMD also sells weight-management subscriptions directly to patients. Watch LifeMD’s weight-management subscriber count for demand for this clinical alternative to Medifast’s traditional nutrition plans.
Eli Lilly’s GLP-1 medicines compete for Medifast’s weight-management clients while enlarging the potential customer base for its GLP-1 nutrition support plans. Watch access to Lilly’s treatments: wider use presents both a challenge to Medifast’s traditional plans and an opportunity to sell nutrition support to people taking the drugs.
Novo Nordisk’s GLP-1 therapies offer patients an alternative to Medifast’s traditional weight-loss plans, while creating demand for its GLP-1 nutrition support. Adoption of Novo Nordisk’s treatments is therefore worth watching for both pressure on Medifast’s traditional clients and demand from clients who want nutrition alongside medication.
Simply Good Foods gives consumers retail alternatives to Medifast’s packaged nutrition and OPTAVIA Fuelings through its Atkins, Quest and OWYN products. Its protein-bar and ready-to-drink shake sales through retailers are worth watching for demand for convenient nutrition bought outside Medifast’s coached plans.
BellRing Brands competes with Medifast for consumers seeking convenient protein and calorie-controlled nutrition through its Premier Protein shakes and protein powders. Watch its ready-to-drink shake sales, the main revenue line tied to this alternative to Medifast’s nutrition products.
Medifast, Inc. earningsThis company
Medifast’s report will show whether OPTAVIA’s shift toward metabolic health is rebuilding sales by stabilizing its coach network or increasing sales per active coach.
Read OPTAVIA revenue alongside the number of active earning coaches and average quarterly revenue per active earning coach. Rising revenue with a stabilizing coach count, or more revenue per coach, would show signs of renewed demand or stronger coach productivity; falling revenue and coach numbers would show that the transformation has not yet reversed the contraction.
The Simply Good Foods Company earningsSMPL
Simply Good Foods’ report will show how much demand remains for retail protein bars and ready-to-drink shakes, convenient nutrition alternatives to Medifast’s coached plans.
Look at Simply Good Foods’ sales of protein bars and ready-to-drink shakes. Growth would show continued demand for convenient packaged nutrition, but would not prove that demand for Medifast’s coached plans is rising; weakness would point to pressure in the retail convenience channel, leaving Medifast’s coach network and client retention to show whether its own model still draws customers.
Eli Lilly & Co. earningsLLY
Eli Lilly’s report will show what demand and access for its GLP-1 medicines mean for competition with Medifast’s traditional plans and potential demand for nutrition support.
Read Lilly’s reported demand for its GLP-1 medicines alongside what it says about supply and access. If more patients can obtain them, they may compete more strongly with Medifast’s traditional plans, while also expanding the potential need for nutrition support during treatment; constrained access would limit the immediate pressure but would not show that interest in the medicines has faded. Lilly’s report reveals the two-sided exposure, not how many customers Medifast will gain.
Herbalife Ltd. earningsHLF
Herbalife’s report will show demand for nutrition and weight-management products supported by an independent network, the model most like Medifast’s coached plans.
Look at Herbalife’s reported meal-replacement and weight-management sales, then compare the picture with Medifast’s OPTAVIA sales and active coach count. Firm sales would show that customers still buy nutrition plans with guidance; weakness would point to pressure on that model. The companies do not have the same customers or products, so the report describes the setting for Medifast’s coached approach, not Medifast’s own results.
LifeMD, Inc. earningsLFMD
LifeMD’s report will show whether more patients are choosing online clinical weight-management subscriptions, an alternative to Medifast’s coach-led nutrition plans.
Look at LifeMD’s weight-management subscriber count. Growth would show that more patients are choosing online clinical care, giving Medifast’s coached plans more competition; a decline would point to less momentum for that channel. The count does not show how many Medifast clients use LifeMD’s platform or, by itself, how well Medifast’s nutrition-support plans are selling.
